Challenges in monoclonal antibody-based therapies

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256: 495–7
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005; 23: 1073–8
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000; 355: 735–40
   PubMed Web of Science ®Google Scholar
• Stocks M. Intrabodies as drug discovery tools and therapeutics. Curr Opin Chem Biol. 2005; 9: 359–65
   PubMed Web of Science ®Google Scholar
• Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol. 2004; 113: 171–82
   PubMed Web of Science ®Google Scholar
• Marasco WA. Therapeutic antibody gene transfer. Nat Biotechnol. 2005; 23: 551–2
   Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11: 81–8
   PubMed Web of Science ®Google Scholar
• Pelegrin M, Gros L, Dreja H, Piechaczyk M. Monoclonal antibody-based genetic immunotherapy. Curr Gene Ther. 2004; 4: 347–56
   Google Scholar
• Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006; 5: 147–59
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601–8
   PubMed Web of Science ®Google Scholar
• Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000; 296: 57–86
   PubMed Web of Science ®Google Scholar
• Lonberg, N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol. 2008:69–97.
   Google Scholar
• Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005; 24: 487–99
   PubMed Web of Science ®Google Scholar
• Directive 75/318/EEC. Production and quality control of monoclonal antibodies. 2007. Ref Type: Generic., http://www.emea.europa.eu/pdfs/human/bwp/3ab4aen.pdf
   Google Scholar
• Sethuraman N, Stadheim TA. Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol. 2006; 17: 341–6
   PubMed Web of Science ®Google Scholar
• Butler M. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems. Cytotechnology. 2006; 50: 57–76
   PubMed Web of Science ®Google Scholar
• Werner RG, Noe W, Kopp K, Schluter M. Appropriate mammalian expression systems for biopharmaceuticals. Arzneimittelforschung. 1998; 48: 870–80
   PubMed Web of Science ®Google Scholar
• Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl. 2007; 96: 17–22
   PubMedGoogle Scholar
• Costello JC, Halverson PB. A new era in rheumatoid arthritis treatment. WMJ. 2003; 102: 29–33
   PubMedGoogle Scholar
• Finesilver AG. Newer approaches to the treatment of rheumatoid arthritis. WMJ. 2003; 102: 34–7
   Google Scholar
• Toi M, Takada M, Bando H, Toyama K, Yamashiro H, Horiguchi S, et al. Current status of antibody therapy for breast cancer. Breast Cancer. 2004; 11: 10–4
   Google Scholar
• Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005; 23: 584–90
   PubMedGoogle Scholar
• Das, RC. Proteins and antibodies make advances as therapeutic products. Am Clin Lab. 2001;20:8, 10–8, 14.
   Google Scholar
• Zhou JX, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Prog. 2006; 22: 341–9
   PubMed Web of Science ®Google Scholar
• Berenson, A. A cancer drug shows promise, at a price that many can't pay. New York Times. 2006, Jun 15.
   Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93: 2645–68
   PubMed Web of Science ®Google Scholar
• Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004; 93: 2184–204
   PubMed Web of Science ®Google Scholar
• Metzler B, Li C, Hu Y, Sturm G, Ghaffari-Tabrizi N, Xu Q. LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999; 19: 1862–71
   Google Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992; 52: 3402–8
   PubMed Web of Science ®Google Scholar
• Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks. Trends Immunol. 2004; 25: 85–91
   PubMed Web of Science ®Google Scholar
• Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005; 5((Suppl 1))S37–47
   PubMed Web of Science ®Google Scholar
• Gruber R, van Haarlem LJ, Warnaar SO, Holz E, Riethmuller G. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 2000; 60: 1921–6
   PubMed Web of Science ®Google Scholar
• Isaacs JD. The antiglobulin response to therapeutic antibodies. Semin Immunol. 1990; 2: 449–56
   PubMedGoogle Scholar
• Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?. Clin Diagn Lab Immunol. 1994; 1: 365–72
   PubMedGoogle Scholar
• Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000; 18: 3135–43
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999; 288: 371–8
   PubMed Web of Science ®Google Scholar
• Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS. 2002; 16: 227–33
   PubMed Web of Science ®Google Scholar
• Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004; 21: 897–903
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003; 9: 269–77
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005; 23: 1147–57
   PubMed Web of Science ®Google Scholar
• Wawrzynczak, EJ. Antibody Therapy. Oxford: BIOS Scientific Publishers Ltd; 1995.
   Google Scholar
• Bruggemann M, Taussig MJ. Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol. 1997; 8: 455–8
   PubMedGoogle Scholar
• Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 1997; 15: 146–56
   PubMed Web of Science ®Google Scholar
• Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal. 2005; 39: 364–75
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783–92
   PubMed Web of Science ®Google Scholar
• Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002; 13: 1948–50
   PubMed Web of Science ®Google Scholar
• Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti—epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19: 3234–43
   PubMed Web of Science ®Google Scholar
• Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002; 29((Suppl 4))27–36
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–42
   PubMed Web of Science ®Google Scholar
• Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005; 12: 189–211
   PubMed Web of Science ®Google Scholar
• Orive G, Gascon AR, Hernandez RM, Igartua M, Luis PJ. Cell microencapsulation technology for biomedical purposes: novel insights and challenges. Trends Pharmacol Sci. 2003; 24: 207–10
   PubMed Web of Science ®Google Scholar
• Orive G, Hernandez RM, Gascon AR, Igartua M, Pedraz JL. Encapsulated cell technology: from research to market. Trends Biotechnol. 2002; 20: 382–7
   PubMed Web of Science ®Google Scholar
• Pelegrin M, Marin M, Oates A, Noel D, Saller R, Salmons B, et al. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum Gene Ther. 2000; 11: 1407–15
   PubMed Web of Science ®Google Scholar
• Lamikanra A, Myers KA, Ferris N, Mitrophanous KA, Carroll MW. In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. Gene Ther. 2005; 12: 988–98
   Google Scholar
• Herzog RW. Recent advances in hepatic gene transfer: more efficacy and less immunogenicity. Curr Opin Drug Discov Devel. 2005; 8: 199–206
   Google Scholar
• Noel D, Pelegrin M, Marin M, Biard-Piechaczyk M, Ourlin JC, Mani JC, et al. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum Gene Ther. 1997; 8: 1219–29
   PubMedGoogle Scholar
• Noel D, Pelegrin M, Kramer S, Jacquet C, Skander N, Piechaczyk M. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther. 2002; 13: 1483–93
   PubMedGoogle Scholar
• Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol. 2002; 76: 8769–75
   PubMed Web of Science ®Google Scholar
• Arafat WO, Gomez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002; 9: 256–62
   PubMedGoogle Scholar
• Whittington HA, Ashworth LJ, Hawkins RE. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Ther. 1998; 5: 770–7
   PubMedGoogle Scholar
• Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 2006; 12((20 Pt 1))6179–85
   Google Scholar
• Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005; 79: 14793–803
   PubMed Web of Science ®Google Scholar
• Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 2003; 77: 3495–504
   PubMed Web of Science ®Google Scholar
• Duan L, Laughlin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A. 1998; 95: 10344
   Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302: 415–9
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hacein-Bey-Abina S, Wissler M, Carlier F, Lim A, Prinz C, et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood. 2005; 105: 2699–706
   PubMed Web of Science ®Google Scholar
• Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther. 2004; 9: 328–36
   PubMed Web of Science ®Google Scholar
• Whittington HA, Ashworth LJ, Hawkins RE. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Ther. 1998; 5: 770–7
   PubMedGoogle Scholar
• Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegrin M. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther. 2004; 2: 2
   PubMedGoogle Scholar